<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if	✓ Methods and Materials/paragraph 1	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	✓ Methods and Materials/paragraph 2	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	Not applicable.	~

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	Not applicable.	~
Animal observed in or captured from the field: Provide species, sex and age where possible	Not applicable.	~
Model organisms: Provide Accession number in repository (where relevant) OR RRID	Not applicable.	~

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	Not applicable.	/
Microbes: provide species and strain, unique accession number if available, and source	Not applicable.	~

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	✓ Ethical Statement/paragraph 1	
Provide statement confirming informed consent obtained from study participants.	✓ Ethical Statement/paragraph 1	
Report on age and sex for all study participants.	✓ Ethical Statement/paragraph 1	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	✓ Ethical Statement/paragraph 1	
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	Not applicable.	~
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination	Not applicable.	V
Randomisation	Not applicable.	~
Blinding	Not applicable.	~
Inclusion/exclusion criteria	Not applicable.	~
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	✓ Methods and Materials/paragraph 4-11	12/12
Define whether data describe technical or biological replicates	✓ Methods and Materials/paragraph 4-11	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	✓ Ethical Statement/paragraph 1	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Not applicable.	~
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Not applicable.	~
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	Not applicable.	~

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Not applicable.	~

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	✓ Methods and Materials/paragraph 14	
tests.		

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Not applicable.	<
If data are publicly available, provide accession number in repository or DOI or URL.	Not applicable.	~
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Not applicable.	'

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	Not applicable.	~
If code is publicly available, provide accession number in repository, or DOI or URL.	Not applicable.	~

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a	ICMJE recommendations for publication.	
checklist (eg., CONSORT, PRISMA, ARRIVE) is		
provided with the manuscript.		

Article information: https://dx.doi.org/10.21037/atm-22-757